Biomea Fusion, Inc. Forms 3, 4 and 5: Stock Options
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 71 rows, 71 shown. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2026-06-10: Reporting owner Faust Elizabeth; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2026-06-10: Reporting owner AGUIAR ERIC; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2026-06-10: Reporting owner Ray Sumita; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2026-06-10: Reporting owner Averill Julianne; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
BMEA insiders transactions against the stock price
Blue: Split-adjusted close · Orange: Cumulative dividend-reinvested close
Logarithmic scale. Both lines share the same starting value for the selected range.
Markers: each transaction type positioned at that session's split-adjusted close. Tooltips retain the reported transaction price when available.
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-06-10 | Faust Elizabeth Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +196,299 196,299 owned after | $1.15 exercise price | $1.15 | 2026-06-12 |
| 2026-06-10 | AGUIAR ERIC Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +196,299 196,299 owned after | $1.15 exercise price | $1.15 | 2026-06-12 |
| 2026-06-10 | Ray Sumita Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +196,299 196,299 owned after | $1.15 exercise price | $1.15 | 2026-06-12 |
| 2026-06-10 | Averill Julianne Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +173,711 173,711 owned after | $1.15 exercise price | $1.15 | 2026-06-12 |
| 2026-04-01 | Erdtmann Rainer M Director, Officer (See Remarks) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +452,512 452,512 owned after | $1.49 exercise price | $1.49 | 2026-04-03 |
| 2026-04-01 | Hitchcock Michael J.M. Director, Officer (Interim CEO) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +667,477 667,477 owned after | $1.49 exercise price | $1.49 | 2026-04-03 |
| 2025-08-11 | Hitchcock Michael J.M. Director, Officer (Interim CEO) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +916,434 916,434 owned after | $1.53 exercise price | $1.53 | 2025-08-13 |
| 2025-08-11 | Erdtmann Rainer M Director, Officer (See Remarks) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +1,246,989 1,246,989 owned after | $1.53 exercise price | $1.53 | 2025-08-13 |
| 2025-08-01 holding as of filing | Chen Bihua | Cormorant Asset Management, LP | Cormorant Global Healthcare Master Fund, LP | Cormorant Private Healthcare Fund III LP Other (Former Director) | Other (Former 10% Holder) | Other (Former 10% Holder) | Other (Former 10% Holder) | 4 | Stock Option (right to buy) Derivative · Direct | Holding | 28,911 owned after | $17.00 exercise price | 2025-08-01 | |
| 2025-08-01 holding as of filing | Chen Bihua | Cormorant Asset Management, LP | Cormorant Global Healthcare Master Fund, LP | Cormorant Private Healthcare Fund III LP Other (Former Director) | Other (Former 10% Holder) | Other (Former 10% Holder) | Other (Former 10% Holder) | 4 | Stock Option (right to buy) Derivative · Direct | Holding | 23,867 owned after | $10.20 exercise price | 2025-08-01 | |
| 2025-08-01 holding as of filing | Chen Bihua | Cormorant Asset Management, LP | Cormorant Global Healthcare Master Fund, LP | Cormorant Private Healthcare Fund III LP Other (Former Director) | Other (Former 10% Holder) | Other (Former 10% Holder) | Other (Former 10% Holder) | 4 | Stock Option (right to buy) Derivative · Direct | Holding | 6,989 owned after | $38.90 exercise price | 2025-08-01 | |
| 2025-08-01 holding as of filing | Chen Bihua | Cormorant Asset Management, LP | Cormorant Global Healthcare Master Fund, LP | Cormorant Private Healthcare Fund III LP Other (Former Director) | Other (Former 10% Holder) | Other (Former 10% Holder) | Other (Former 10% Holder) | 4 | Stock Option (right to buy) Derivative · Direct | Holding | 51,025 owned after | $4.63 exercise price | 2025-08-01 | |
| 2025-08-01 holding as of filing | Chen Bihua | Cormorant Asset Management, LP | Cormorant Global Healthcare Master Fund, LP | Cormorant Private Healthcare Fund III LP Other (Former Director) | Other (Former 10% Holder) | Other (Former 10% Holder) | Other (Former 10% Holder) | 4 | Stock Option (Right to Buy) Derivative · Direct | Holding | 91,970 owned after | $2.50 exercise price | 2025-08-01 | |
| 2025-07-22 | Averill Julianne Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +241,177 241,177 owned after | $1.82 exercise price | $1.82 | 2025-07-24 |
| 2025-06-13 holding as of filing | Chen Bihua | Cormorant Global Healthcare Master Fund, LP | Cormorant Asset Management, LP | Cormorant Private Healthcare Fund III LP Director, 10% Owner | 10% Owner | 10% Owner | 10% Owner | 4 | Stock Option (right to buy) Derivative · Direct | Holding | 28,911 owned after | $17.00 exercise price | 2025-06-13 | |
| 2025-06-13 holding as of filing | Chen Bihua | Cormorant Global Healthcare Master Fund, LP | Cormorant Asset Management, LP | Cormorant Private Healthcare Fund III LP Director, 10% Owner | 10% Owner | 10% Owner | 10% Owner | 4 | Stock Option (right to buy) Derivative · Direct | Holding | 23,867 owned after | $10.20 exercise price | 2025-06-13 | |
| 2025-06-13 holding as of filing | Chen Bihua | Cormorant Global Healthcare Master Fund, LP | Cormorant Asset Management, LP | Cormorant Private Healthcare Fund III LP Director, 10% Owner | 10% Owner | 10% Owner | 10% Owner | 4 | Stock Option (right to buy) Derivative · Direct | Holding | 6,989 owned after | $38.90 exercise price | 2025-06-13 | |
| 2025-06-13 holding as of filing | Chen Bihua | Cormorant Global Healthcare Master Fund, LP | Cormorant Asset Management, LP | Cormorant Private Healthcare Fund III LP Director, 10% Owner | 10% Owner | 10% Owner | 10% Owner | 4 | Stock Option (right to buy) Derivative · Direct | Holding | 51,025 owned after | $4.63 exercise price | 2025-06-13 | |
| 2025-06-11 | Faust Elizabeth Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +91,970 91,970 owned after | $2.50 exercise price | $2.50 | 2025-06-13 |
| 2025-06-11 | AGUIAR ERIC Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +91,970 91,970 owned after | $2.50 exercise price | $2.50 | 2025-06-13 |
| 2025-06-11 | Ray Sumita Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +91,970 91,970 owned after | $2.50 exercise price | $2.50 | 2025-06-13 |
| 2025-06-11 | Chen Bihua | Cormorant Global Healthcare Master Fund, LP | Cormorant Asset Management, LP | Cormorant Private Healthcare Fund III LP Director, 10% Owner | 10% Owner | 10% Owner | 10% Owner | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +91,970 91,970 owned after | $2.50 exercise price | $2.50 | 2025-06-13 |
| 2025-03-26 | Hitchcock Michael J.M. Director, Officer (Interim CEO) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +350,000 350,000 owned after | $2.52 exercise price | $2.52 | 2025-03-28 |
| 2024-06-13 holding as of filing | Cormorant Global Healthcare Master Fund, LP | Chen Bihua | Cormorant Private Healthcare Fund III LP | Cormorant Asset Management, LP 10% Owner | Director, 10% Owner | 10% Owner | 10% Owner | 4 | Stock Option (right to buy) Derivative · Direct | Holding | 28,911 owned after | $17.00 exercise price | 2024-06-13 | |
| 2024-06-13 holding as of filing | Cormorant Global Healthcare Master Fund, LP | Chen Bihua | Cormorant Private Healthcare Fund III LP | Cormorant Asset Management, LP 10% Owner | Director, 10% Owner | 10% Owner | 10% Owner | 4 | Stock Option (right to buy) Derivative · Direct | Holding | 23,867 owned after | $10.20 exercise price | 2024-06-13 | |
| 2024-06-13 holding as of filing | Cormorant Global Healthcare Master Fund, LP | Chen Bihua | Cormorant Private Healthcare Fund III LP | Cormorant Asset Management, LP 10% Owner | Director, 10% Owner | 10% Owner | 10% Owner | 4 | Stock Option (right to buy) Derivative · Direct | Holding | 6,989 owned after | $38.90 exercise price | 2024-06-13 | |
| 2024-06-12 | Cormorant Global Healthcare Master Fund, LP | Chen Bihua | Cormorant Private Healthcare Fund III LP | Cormorant Asset Management, LP 10% Owner | Director, 10% Owner | 10% Owner | 10% Owner | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +51,025 51 owned after | $4.63 exercise price | $4.63 | 2024-06-13 |
| 2024-06-12 | Ray Sumita Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +51,025 51,025 owned after | $4.63 exercise price | $4.63 | 2024-06-13 |
| 2024-06-12 | Faust Elizabeth Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +51,025 51,025 owned after | $4.63 exercise price | $4.63 | 2024-06-13 |
| 2024-06-12 | Hitchcock Michael J.M. Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +51,025 51,025 owned after | $4.63 exercise price | $4.63 | 2024-06-13 |
| 2024-06-12 | AGUIAR ERIC Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +51,025 51,025 owned after | $4.63 exercise price | $4.63 | 2024-06-13 |
| 2024-01-17 | Butler Thomas Andrew Director, Officer (Chief Executive Officer), 10% Owner | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +407,502 407,502 owned after | $14.44 exercise price | $14.44 | 2024-01-18 |
| 2024-01-17 | Erdtmann Rainer M Director, Officer (President and COO) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +135,700 135,700 owned after | $14.44 exercise price | $14.44 | 2024-01-18 |
| 2024-01-17 | Valle Franco Officer (Chief Financial Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +145,245 145,245 owned after | $14.44 exercise price | $14.44 | 2024-01-18 |
| 2024-01-17 | Frias Juan Pablo Officer (Chief Medical Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +111,090 111,090 owned after | $14.44 exercise price | $14.44 | 2024-01-18 |
| 2023-08-31 | Frias Juan Pablo Officer (Chief Medical Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +300,000 300,000 owned after | $16.87 exercise price | $16.87 | 2023-09-01 |
| 2023-06-16 holding as of filing | Chen Bihua | Cormorant Asset Management, LP | Cormorant Private Healthcare Fund III LP | Cormorant Global Healthcare Master Fund, LP Director, 10% Owner | 10% Owner | 10% Owner | 10% Owner | 4 | Stock Option (right to buy) Derivative · Direct | Holding | 28,911 owned after | $17.00 exercise price | 2023-06-16 | |
| 2023-06-16 holding as of filing | Chen Bihua | Cormorant Asset Management, LP | Cormorant Private Healthcare Fund III LP | Cormorant Global Healthcare Master Fund, LP Director, 10% Owner | 10% Owner | 10% Owner | 10% Owner | 4 | Stock Option (right to buy) Derivative · Direct | Holding | 23,867 owned after | $10.20 exercise price | 2023-06-16 | |
| 2023-06-14 | Hitchcock Michael J.M. Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +6,989 6,989 owned after | $38.90 exercise price | $38.90 | 2023-06-16 |
| 2023-06-14 | Chen Bihua | Cormorant Asset Management, LP | Cormorant Private Healthcare Fund III LP | Cormorant Global Healthcare Master Fund, LP Director, 10% Owner | 10% Owner | 10% Owner | 10% Owner | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +6,989 6,989 owned after | $38.90 exercise price | $38.90 | 2023-06-16 |
| 2023-06-14 | Faust Elizabeth Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +6,989 6,989 owned after | $38.90 exercise price | $38.90 | 2023-06-16 |
| 2023-06-14 | Ray Sumita Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +6,989 6,989 owned after | $38.90 exercise price | $38.90 | 2023-06-16 |
| 2023-06-14 | AGUIAR ERIC Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +6,989 6,989 owned after | $38.90 exercise price | $38.90 | 2023-06-16 |
| 2023-04-03 holding as of filing | Cormorant Global Healthcare Master Fund, LP | Cormorant Asset Management, LP | Chen Bihua | Cormorant Private Healthcare Fund III LP 10% Owner | 10% Owner | Director, 10% Owner | 10% Owner | 4 | Stock Option (right to buy) Derivative · Direct | Holding | 28,911 owned after | $17.00 exercise price | 2023-04-03 | |
| 2023-04-03 holding as of filing | Cormorant Global Healthcare Master Fund, LP | Cormorant Asset Management, LP | Chen Bihua | Cormorant Private Healthcare Fund III LP 10% Owner | 10% Owner | Director, 10% Owner | 10% Owner | 4 | Stock Option (right to buy) Derivative · Direct | Holding | 23,867 owned after | $10.20 exercise price | 2023-04-03 | |
| 2023-01-06 | Erdtmann Rainer M Director, Officer (President and COO) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +118,000 118,000 owned after | $7.05 exercise price | $7.05 | 2023-01-10 |
| 2023-01-06 | Valle Franco Officer (Chief Financial Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +126,300 126,300 owned after | $7.05 exercise price | $7.05 | 2023-01-10 |
| 2023-01-06 | Butler Thomas Andrew Director, Officer (Chief Executive Officer), 10% Owner | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +354,350 354,350 owned after | $7.05 exercise price | $7.05 | 2023-01-10 |
| 2022-06-24 holding as of filing | Cormorant Asset Management, LP | Chen Bihua | Cormorant Private Healthcare Fund III LP | Cormorant Global Healthcare Master Fund, LP 10% Owner | Director, 10% Owner | 10% Owner | 10% Owner | 4 | Stock Option (right to buy) Derivative · Direct | Holding | 28,911 owned after | $17.00 exercise price | 2022-06-24 | |
| 2022-06-22 | Ray Sumita Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +23,867 23,867 owned after | $10.20 exercise price | $10.20 | 2022-06-24 |
| 2022-06-22 | Hitchcock Michael J.M. Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +23,867 23,867 owned after | $10.20 exercise price | $10.20 | 2022-06-24 |
| 2022-06-22 | AGUIAR ERIC Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +23,867 23,867 owned after | $10.20 exercise price | $10.20 | 2022-06-24 |
| 2022-06-22 | Faust Elizabeth Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +45,755 45,755 owned after | $10.20 exercise price | $10.20 | 2022-06-24 |
| 2022-06-22 | Cormorant Asset Management, LP | Chen Bihua | Cormorant Private Healthcare Fund III LP | Cormorant Global Healthcare Master Fund, LP 10% Owner | Director, 10% Owner | 10% Owner | 10% Owner | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +23,867 23,867 owned after | $10.20 exercise price | $10.20 | 2022-06-24 |
| 2022-03-03 | Ray Sumita Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +21,461 21,461 owned after | $5.90 exercise price | $5.90 | 2022-03-07 |
| 2021-12-04 | Butler Thomas Andrew Director, Officer (CEO), 10% Owner | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +305,400 305,400 owned after | $9.80 exercise price | $9.80 | 2021-12-07 |
| 2021-12-04 | Erdtmann Rainer M Director, Officer (President & COO), 10% Owner | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +165,490 165,490 owned after | $9.80 exercise price | $9.80 | 2021-12-07 |
| 2021-12-04 | Valle Franco Officer (Chief Financial Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +144,770 144,770 owned after | $9.80 exercise price | $9.80 | 2021-12-07 |
| 2021-08-03 | Valle Franco Officer (Chief Financial Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +165,000 165,000 owned after | $13.45 exercise price | $13.45 | 2021-08-05 |
| 2021-06-16 | Ray Sumita Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +17,724 17,724 owned after | $20.46 exercise price | $20.46 | 2021-06-21 |
| 2021-04-22 holding as of filing | Cormorant Asset Management, LP | Cormorant Private Healthcare Fund III LP | Chen Bihua | Cormorant Global Healthcare Master Fund, LP 10% Owner | 10% Owner | Director | 10% Owner | 4 | Stock Option (right to buy) Derivative · Direct | Holding | 28,911 owned after | $17.00 exercise price | 2021-04-22 | |
| 2021-04-15 | Cormorant Private Healthcare Fund III LP | Cormorant Global Healthcare Master Fund, LP | Chen Bihua | Cormorant Asset Management, LP 10% Owner | 10% Owner | Director, 10% Owner | Director, 10% Owner | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | −28,911 28,911 owned after | $17.00 exercise price | 2021-04-19 | |
| 2021-04-15 | AGUIAR ERIC Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +28,911 28,911 owned after | $17.00 exercise price | 2021-04-19 | |
| 2021-04-15 | Stergiopoulos Sotirios Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +28,911 28,911 owned after | $17.00 exercise price | 2021-04-19 | |
| 2021-04-15 | Hitchcock Michael J.M. Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +28,911 28,911 owned after | $17.00 exercise price | 2021-04-19 | |
| 2021-04-15 holding as of filing | Erdtmann Rainer M Director, Officer (President and COO), 10% Owner | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $5.14 exercise price | 2021-04-15 | ||
| 2021-04-15 holding as of filing | Erdtmann Rainer M Director, Officer (President and COO), 10% Owner | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $7.50 exercise price | 2021-04-15 | ||
| 2021-04-15 holding as of filing | Butler Thomas Andrew Director, Officer (CEO), 10% Owner | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $5.14 exercise price | 2021-04-15 | ||
| 2021-04-15 holding as of filing | Butler Thomas Andrew Director, Officer (CEO), 10% Owner | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $7.50 exercise price | 2021-04-15 | ||
| 2021-04-15 holding as of filing | Ryan Sunny Officer (EVP of Finance) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $5.14 exercise price | 2021-04-15 | ||
| 2021-04-15 holding as of filing | Ryan Sunny Officer (EVP of Finance) | 3 | Stock Option (Right to Buy Derivative · Direct | Holding | $7.50 exercise price | 2021-04-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B |